Skip to search formSkip to main contentSkip to account menu

Metastatic Disease Clinical Trial Setting

Known as: METASTATIC 
A clinical trial or treatment setting in which the therapy of interest is used to treat metastatic disease.
National Institutes of Health

Related topics

Related topics

2 relations
CDISC SDTM Treatment Setting TerminologyClinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract OT1-04-06: NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) &/or surgical ablation for newly oligometastatic breast cancer
Background: The current standard of care for metastatic breast cancer patients (pts) is to deliver palliative chemotherapy… 
2016
2016
Abstract OT2-01-06: Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER+/AR+ breast…
Background: Historically, androgens have been utilized for the treatment of BC as the androgen receptor (AR) is the most highly… 
2016
2016
Metastatic clear cell renal carcinoma – an unusual response to Temsirolimus in second line therapy
Renal cell carcinoma (RCC) represents 3% of all cancers, with the highest incidence occurring in the most developed countries and… 
2016
2016
MB-03LONG TERM FOLLOW-UP OF PATIENTS WITH METASTATIC (M+) AND OTHER HIGH-RISK MEDULLOBLASTOMA WITH TAILORED-DOSES HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (HART) CRANIOSPINAL IRRADIATION (CSI) PLUS…
2016
2016
EAU Position Piece The Role of Cytoreductive Nephrectomy : The Current EAU Position
a Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; b… 
2011
2011
Global Characterization of Protein-Altering Mutations in Prostate Cancer
Abstract : The identification of recurrent, protein-altering genetic alterations is frequently the means by which a given gene is… 
2010
2010
An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.
e14503 Background: Since sunitinib is effective in metastatic renal cancer and GIST tumors, we evaluated tolerability and… 
2010
2010
Guideline adherence rates of chemotherapy treatment for breast cancer patients treated in U.S. community oncology practices.
596 Background: Adherence to national guidelines is a key step to improving the quality of cancer treatment. This study examined… 
2008
2008
Trends in trastuzumab utilization in Ontario: A single payer system
11534 Background: Ontario, a province of 13 million, has a single payer system for new IV cancer drugs, the New Drug Funding… 
2005
2005
Thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), ERCC1, & thymidine phosphorylase gene expression in primary & metastatic (met) colorectal cancer (CRC) tissue in patients (pts…
3549 Background: Overexpression of TS/DPD & ERCC1 in tumor tissue have been associated with insensitivity to 5-FU and OX therapy…